SIPONIMOD

S1P Receptor Modulator

Brand names: MAYZENT, Mayzent

Oral

Mechanism of Action

12.1 Mechanism of Action Siponimod is an S1P receptor modulator. Siponimod binds with high affinity to S1P receptors 1 and 5. Siponimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which siponimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.

Indications

1 INDICATIONS AND USAGE MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

in adults. MAYZENT is a sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

Contraindications

• unstable angina
• stroke
• TIA
• decompensated heart failure requiring hospitalization
• or Class III or IV heart failure Presence of Mobitz type II second-degree

FDA Warnings

5 WARNINGS AND PRECAUTIONS Infections: MAYZENT may increase the risk
2 ) Macular Edema: Increases the risk of macular edema
Diabetes mellitus and uveitis increase the risk
8 ) Fetal Risk: Women of childbearing potential should use effective contraception during and for 10 days after stopping MAYZENT

Known Side Effects

8 documented side effects by frequency

Fatigue

>10%

Headache

>10%

Dizziness

1-10%

Falls

1-10%

Drug Not Working

1-10%

Nausea

1-10%

UTI

0.1-1%

Weakness

0.1-1%

Community Discussions

No community discussions found for SIPONIMOD yet.

Compare With

9 available comparisons

Formulations

Dosage Forms

Tablet

Route

Oral